Hoth Therapeutics Reports Q1 2026 Financial Results with $2.69M Net Loss

Hoth Therapeutics, Inc. reported its financial results for the first quarter of 2026, revealing a net loss of approximately $2.69 million, or $0.17 per share, compared to a net loss of $3.48 million, or $0.27 per share, for the same period in 2025. The company did not generate any revenue during the quarter, maintaining its status as a clinical-stage biopharmaceutical firm focused on developing therapies for unmet medical needs. The decrease in net loss reflects a reduction in operating expenses, which totaled $2.65 million for the quarter, down from $3.48 million in the prior year.

The company's operating expenses were primarily driven by research and development costs, which amounted to $1.52 million, a decrease from $1.96 million in the previous year. This reduction was attributed to lower spending on various projects, including a significant decrease in costs associated with the HT-001 project. General and administrative expenses also fell to $1.13 million from $1.52 million, largely due to decreased compensation and consulting fees. The company anticipates that its operating costs will continue to rise as it advances its product candidates and potentially acquires new ones.

As of March 31, 2026, Hoth Therapeutics reported total assets of approximately $5.59 million, a decline from $7.60 million at the end of 2025. The decrease in assets was primarily due to a reduction in cash and cash equivalents, which fell to $4.05 million from $6.25 million. The company’s accumulated deficit increased to $75.57 million, reflecting ongoing operational losses. Hoth Therapeutics also reported working capital of approximately $3.43 million, indicating a need for additional capital to sustain its operations.

In terms of strategic developments, Hoth Therapeutics entered into a securities purchase agreement on April 1, 2026, to sell 2,857,144 shares of common stock at $0.70 per share, raising approximately $2 million in gross proceeds. This offering is part of the company's ongoing efforts to secure funding through equity sales, which have been crucial for financing its research and development activities. The company also updated its At The Market Offering Agreement, allowing for the sale of additional shares, which could provide further capital.

Looking ahead, Hoth Therapeutics faces significant challenges in securing the necessary funding to continue its operations and development plans. The company has indicated that its current cash reserves may not be sufficient to cover its operating expenses for the next 12 months, raising substantial doubt about its ability to continue as a going concern. The management is actively exploring various financing options, including public and private equity offerings, to support its ongoing research and development initiatives.